GFAP and Alzheimer disease: Moreover, levels of GFAP tended to decrease (p ≤ 0.1) after treatment, and effect size pointed to a real decrease (r ≥ 0.68), and although differences in interleukin levels were not significant, their values were closer to the NTg interleukin levels than to the untreated 3xTg-AD animals’ levels.